Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TRAW
Traws Pharma, Inc. (TRAW) EV/Sales
As of 16 October 2026, Traws Pharma, Inc. (TRAW) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −135× (March 2022) to 1,244× (February 2021); the current reading is higher than 57% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | — |
| FY2024 | −33.4× | — |
| FY2023 | −18.8× | — |
| FY2022 | −106× | — |
| FY2021 | −53.7× | — |
| FY2020 | 272× | — |
| FY2019 | −7.9× | — |
| FY2018 | −6.7× | — |
| FY2017 | 12.0× | — |
| FY2016 | −2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1.9× | — |
| Jun 2025 | −1.5× | — |
| Mar 2025 | 0.4× | — |
| Dec 2024 | −33.4× | — |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVGN Evogene Ltd. compare | −2.8× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. | 0.3× |
| LEXX Lexaria Bioscience Corp. compare | 2.4× |
| IMNN Imunon, Inc. compare | 8.0× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)